Related Experiment Videos
Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030
Gregory J Dore1, Jason Grebely1
1The Kirby Institute, UNSW Sydney, Sydney, Australia.
Journal of Hepatology
|April 16, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response.
Journal of viral hepatitis·2026
Hepatitis C: innovations in therapeutic interventions and elimination strategies.
Expert review of gastroenterology & hepatology·2026
Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.
JAMA psychiatry·2026
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study.
The International journal on drug policy·2026
New-onset diabetes following SARS-CoV-2 infection in the Omicron era: a matched cohort study.
International journal of epidemiology·2026
EBV-reactive KIR+ CX3CR1+ CD8+ T cells mediate liver transplantation tolerance.
Journal of hepatology·2026
Systemic therapy for HCC: Doublets, triplets and beyond.
Journal of hepatology·2026
Integrating systemic therapy in the earlier stages of liver cancer.
Journal of hepatology·2026
The use of locoregional therapies in cholangiocarcinoma.
Journal of hepatology·2026
Liver transplantation for primary liver cancers in the era of transplant oncology.
Journal of hepatology·2026
Implementing a nicotine cap to make America Healthy Again.
Health affairs scholar·2026
Implementation of public health tasks by Polish municipalities in 2019-2024: a cross-sectional study.
Frontiers in public health·2026
When democracies coerce their health professionals: institutional constraints and policy outcomes across four jurisdictions.
Frontiers in public health·2026